[Retracted] MicroRNA ‑338‑3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACC1
Exp Ther Med. 2024 Apr 8;27(6):245. doi: 10.3892/etm.2024.12533. eCollection 2024 Jun.ABSTRACT[This retracts the article DOI: 10.3892/etm.2019.7644.].PMID:38655040 | PMC:PMC11036350 | DOI:10.3892/etm.2024.12533 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - April 24, 2024 Category: General Medicine Authors: Chunhua Zhang Hui Li Junling Wang Jibei Zhang Xiaoqian Hou Source Type: research
COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff). (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Dirk Schadendorf, Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsov á, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carol Tags: Original Research Source Type: research
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
Cancers of the skin are the most commonly occurring cancers in humans. In fair-skinned populations, up to 95% of keratinocyte skin cancers and 70-95% of cutaneous melanomas are caused by ultraviolet radiation and are thus theoretically preventable. Currently, however, there is no comprehensive global advice on practical steps to be taken to reduce the toll of skin cancer. To address this gap, an expert working group comprising clinicians and researchers from Africa, America, Asia, Australia, and Europe, together with learned societies (European Association of Dermato-Oncology, Euromelanoma, Euroskin, European Union of Medi...
Source: European Journal of Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Claus Garbe, Ana-Maria Forsea, Teresa Amaral, Petr Arenberger, Philippe Autier, Marianne Berwick, Brigitta Boonen, Matilda Bylaite, Veronique del Marmol, Brigitte Dreno, Maria Concetta Fargnoli, Alan C. Geller, Adele C. Green, R üdiger Greinert, Axel Hau Tags: Current Perspective Source Type: research
Influence of Post-radiation Ocular Surface Disorder on Ocular Surgery: A Case Report and Review of the Literature
CONCLUSION: The continuous worsening of clinical symptoms of the disorder of the ocular surface after proton beam radiotherapy can be the result of a post-radiation syndrome. Gradual expansion of ischemia, vasculitis, and inflammatory mediators compresses the retinal tissue, leading to recurrent macular edema as well as to secondary glaucoma and corneal decompensation. Band keratopathy is occasionally noted and seems to result from severe post-radiation disorder of the ocular surface. However, PKP would typically be indicated in cases of corneal perforation, uncontrolled infectious keratitis, or for improving vision in the...
Source: Klinische Monatsblatter fur Augenheilkunde - April 23, 2024 Category: Opthalmology Authors: Driton Gjukaj Ilir Morina Christophe Valmaggia Dagmar Ammann Margarita G Todorova Source Type: research
GSE255541 Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition
Contributor : Steven P AngusSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensApproximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss of function mutations occur in 40% of BRAFV600E melanomas, resulting in increased PI3K/AKT activity that enhances resistance to BRAF/MEK combination inhibitor therapy. To compare the response of PTEN null to PTEN wild type cells in an isogenic background, CRISPR was used to knock out PTEN a melanoma ...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Sensors, Vol. 24, Pages 2670: Compressed Sensing for Biomedical Photoacoustic Imaging: A Review
This article provides a detailed introduction to PAI based on compressed sensing, such as the physical transmission model-based compressed sensing method, two-stage reconstruction-based compressed sensing method, and single-pixel camera-based compressed sensing method. Challenges and future perspectives of compressed sensing-based PAI are also discussed. (Source: Sensors)
Source: Sensors - April 23, 2024 Category: Biotechnology Authors: Wang Chen Zhao Liu Tags: Review Source Type: research
A novel multifunctional microneedle patch for synergistic photothermal- gas therapy against maxillofacial malignant melanoma and associated skin defects
Considering the high recrudescence and the long-lasting unhealed large-sized wound that affect the aesthetics and cause dysfunction after resection of maxillofacial malignant skin tumors, a groundbreaking stra... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - April 23, 2024 Category: Nanotechnology Authors: Shaojie Dong, Yuwei Zhang, Yifei Zhang, Yukun Mei, Ahmadi Sina, Rui Zou and Lin Niu Tags: Research Source Type: research
The diagnostic performance of [18F]FDG PET/CT in the detection of melanoma recurrence: a systematic review and meta-analysis
ConclusionIt finds that [18F]FDG PET/CT has excellent diagnosis performance in identifying malignant melanoma recurrence. Its application could improve patient prognosis by detecting and treating recurrences earlier. Further studies need more prospective large samples. (Source: Clinical and Translational Imaging)
Source: Clinical and Translational Imaging - April 23, 2024 Category: Radiology Source Type: research
Anoikis patterns via machine learning strategy and experimental verification exhibit distinct prognostic and immune landscapes in melanoma
ConclusionsIn this study, we successfully established a prognostic anoikis-connected signature using machine learning. This model may aid in evaluating patient prognosis, clinical characteristics, and immune treatment modalities for melanoma. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 22, 2024 Category: Cancer & Oncology Source Type: research
Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland
CONCLUSION: In patients with a high risk of NMSC, reducing skin cancer risk should be considered in conjunction with the optimisation of treatment.PMID:38646861 | DOI:10.1111/ajr.13081 (Source: The Australian Journal of Rural Health)
Source: The Australian Journal of Rural Health - April 22, 2024 Category: Rural Health Authors: Zaw Thet Alfred King-Yin Lam Shu-Kay Ng Soe Yu Aung Thin Han Dwarakanathan Ranganathan Stephanie Newsham Jennifer Borg Christine Pepito Tien K Khoo Source Type: research
Sarcoid-Like Reactions to Immune Checkpoint Inhibitors: Incidence, Treatment Course, and Impact on Cancer Progression and Survival
CONCLUSIONS: SLRs are a known but understudied complication associated with ICI therapy. Multisystem SLR patients were more symptomatic and required ICI discontinuation and immune suppression. Larger studies are needed to fully evaluate the impact of SLR on cancer outcomes.PMID:38648910 | DOI:10.1016/j.rmed.2024.107640 (Source: Respiratory Care)
Source: Respiratory Care - April 22, 2024 Category: Respiratory Medicine Authors: Hannah Smith Robert Easterling Jianing Ma Meghana Moodabagil Alexa Meara Dwight H Owen Elliot Crouser Arindam Singha Kevin Ho Source Type: research
Estudio observacional retrospectivo de 35 casos de lentigo maligno y melanoma lentiginoso acral tratados quir úrgicamente mediante una técnica de espagueti modificada
Actas Dermosifiliogr. 2024 Apr 20:S0001-7310(24)00351-X. doi: 10.1016/j.ad.2024.04.011. Online ahead of print.NO ABSTRACTPMID:38648937 | DOI:10.1016/j.ad.2024.04.011 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 22, 2024 Category: Dermatology Authors: E Samaniego Gonz ález M A Gonz ález Morán V Onecha Vallejo A I de la Hera Magallanes M Navedo de Las Heras M Á Rodríguez Prieto Source Type: research
[[Translated article]]Discussion Abounds on the Potential Carcinogenic Risks Associated With the Use of UV Curing Lamps for Permanent Nail Polish
CONCLUSIONS: The exposure times and doses received with the common use of artificial lamp nail drying correspond to sunlight exposures of 3 min to 5 min in the central hours of the day. This represents a very low carcinogenic potential compared to sunlight exposure, although similar regarding immunosuppressive potential. Photoprotective measures would further minimize the risks.PMID:38648931 | DOI:10.1016/j.ad.2024.04.006 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 22, 2024 Category: Dermatology Authors: J Aguilera R J Bosch M V de G álvez Source Type: research
ASO Author Reflections: Exploring the Impact-Medicaid Expansion and Improved Survival in Patients with Cutaneous Melanoma
Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15286-w. Online ahead of print.NO ABSTRACTPMID:38647911 | DOI:10.1245/s10434-024-15286-w (Source: Ann Oncol)
Source: Ann Oncol - April 22, 2024 Category: Cancer & Oncology Authors: Alicia C Greene Olivia Ziegler Colette R Pameijer Chan Shen Source Type: research
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma
In this study, we tested a novel approach of "repurposing" a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2 (the animal homolog to HER2/neu). This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7.16.4). The c-erb-B2-expressing melanoma was designated B16/neu. 7.16.4 produced statist...
Source: Cell Research - April 22, 2024 Category: Cytology Authors: Emmanuel M Gabriel Brian Necela Deborah Bahr Sneha Vivekanandhan Barath Shreeder Sanjay Bagaria Keith L Knutson Source Type: research
